Dystonia in Children and Adolescents: A Systematic Review and a New Diagnostic Algorithm
JNNP 86:774-781, Van Egmond, M.E.,et al, 2015
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Movement Disorders Associated with the Serotonin Selective Reuptake Inhibitors
J Clin Psychiatry 57:449-454, Leo,R.J., 1996
Pleuropulmonary Disease Associated with Dopamine Agonist Therapy
Ann Neurol 30:613-616, Bhatt,M.H.,et al, 1991
Pleuropulmonary & Retroperitoneal Fibrosis Associated with Bromocriptine Treatment
JNNP 50:1706-1707, Ward,C.D.,et al, 1987
The Neuroleptic Malignant Syndrome:Agent and Host Interaction
Acta Psychiatr Scand 73:337-347, Shaley,A.&Munitz,H., 1986
Dystonia-Parkinson Syndrome:Differential Effects of Levodopa and Dopamine Agonists
Clin Neuropharmacol 9:298-302, Klawans,H.L.&Paleologos,N., 1986
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Neuroimaging Biomarkers in a Patient with Probable Psychiatric-Onset Prodromal Dementia with Lewy Bodies
Neurol 99:654-657, Urso, D.,et al, 2022
Clinical and Radiologic Features of Pedicatric Opioid Use-Associated Neurotoxicity with Cerebellar Edema (POUNCE) Syndrome
Neurol 94:710-712, Kim, D.D. & Prasad, A.N., 2020
Involuntary Groaning Induced by Levodopa Therapy in a Patient With Progressive Supranuclear Palsy
JAMA Neurol 77:1569, Park, J.E., 2020
Lithium-Induced Reversible Pisa Syndrome
Neurol 88:e184, Kumar, N.,et al, 2017
A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
High Doses of Deferiprone May Be Associated with Cerebellar Syndrome
BMJ 338:653, Beau-Salinas,F.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008
Reversible Parkinsonism and Ataxia Associated With High-Dose Octreotide
Neurol 70:2345-2346, Espay,A.J., 2008
Fourteen-Year Final Report of the Randomized PDRG-UK Trial Comparing Three Treatments in PD
Neurol 71:474-480.470, Katzenschlager,R.,et al., 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease
Neurol 68:272-276, Watts,R.L.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Quetiapine for Agitation or Psychosis in Patients with Dementia and Parkinsonism
Neurol 68:1356-1363, Kurlan,R.,et al, 2007
Risk Factors for the Development of Pedal Edema in Patients Using Pramipexole
Arch Neurol 64:820-824, Kleiner-Fisman,G. &Fisman,D.N., 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007
Compulsive Singing: Another Aspect of Punding in Parkinsons Disease
Ann Neurol 62:525-528, Bonvin,C.,et al, 2007
Cetirizine-Induced Dystonic Movements
Neurol 66:143-144, Rajput,A. &Baerg,K., 2006
Hiccups Associated with Dopamine Agonists in Parkinson Disease
Neurol 66:774-775, Sharma,P.,et al, 2006
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Safety of Rasagiline in Elderly Patients with Parkinson Disease
Neurol 66:1427-1429, Goetz,C.G.,et al, 2006
Prospective Prevalence of Pathologic Gambling and Medication Association in Parkinson Disease
Neurol 66:1750-1752, Voon,V.,et al, 2006
Reversible Dementia with Parkinsonian Features Associated with Budesonide Use
Neurol 67:723, Proda,C.I.,et al, 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005